stock
LYCA · Lycia Therapeutics, Inc.
Insiders net bought $38.30M in 90 days; last 8-K filed Oct 26: bylaws or fiscal year change.
Price
Chart by TradingView
Members see
- Signals: which strategies fired on LYCA, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- News: stories counted once across outlets
What it is
No 10-K on file. Funds and foreign issuers don't file one.
- Sector
- Life Sciences (SEC office)
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year ends
- December
- Exchange
- Nasdaq
- Fractional shares
- No
- Listed options
- No
- Shares outstanding
- Not reported.
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation
Valuation ratios use the live price. Free with an account.
Start free to see thisDeep value
- NCAV
- —
- NCAV per share
- —
- NNWC
- —
- NNWC per share
- —
These figures use the live price. Free with an account.
Expectations
- Free cash flow
- —
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- —
These figures use the live price. Free with an account.
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- —
Health
- Current ratio
- —
- Debt/equity
- —
Growth the price implies: the yearly free cash flow growth that justifies today's value over 10 years, at a 10% discount rate, 3% growth after year 10. The market's assumption, not a forecast.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
No quarterly results reported by SEC for this filer.
- Cash (not reported by this company)
- —Cash: unreported by this company.
- Debt
- —
- Net cash
- —
- Current assets (not reported by this company)
- —Current assets: unreported by this company.
- Current liabilities (not reported by this company)
- —Current liabilities: unreported by this company.
- Working capital
- —
- Total liabilities (not reported by this company)
- —Total liabilities: unreported by this company.
- Assets (not reported by this company)
- —Assets: unreported by this company.
- Equity (not reported by this company)
- —Equity: unreported by this company.
SEC data as of Nov 3, 2026
Ten years
No annual results reported by SEC for this filer.
Company filings
1 offering filing in 12 months
events
- Bylaws or fiscal year changeOct 268-K
5% owners ()
Venrock Healthcare Capital Partners III, L.P.
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy$644,711Oct 30, 7:25 PM ET
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy$37,653,863Oct 27, 6:38 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Hard to borrow: Alpaca will not lend it for shorting
Off-exchange short volume, 20 days
38.4%
Through Nov 2, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
nakagai
Signals on LYCA come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow LYCA free
Comments · 0
No comments yet.